Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
about
Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor designHeterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implicationsA small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.Identifying a kinase network regulating FGF14:Nav1.6 complex assembly using split-luciferase complementation.The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling.Antioxidants inhibit neuronal toxicity in Parkinson's disease-linked LRRK2Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms.Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor.In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.Small-Molecule Inhibitors of LRRK2.
P2860
Q26827527-5B189262-E6C2-49E4-897D-E5A7DB42C99EQ27013695-AC2B8897-A377-455C-8BD6-51916292E89AQ34764609-92C74C96-EAD5-44B5-A410-F1A9ECC431DDQ35557270-2BA24288-2312-4603-BA21-54E849139D6FQ35679501-3FEE4155-2538-4508-AB45-5EDDB5DE7CB9Q35990800-DA9ADA8B-E1D4-48E8-802D-51F743D6E7A6Q38002888-6F80D7D5-B210-447D-9BB3-727054A89538Q38219430-00D72760-E0F0-43BA-8B0E-413B276B5C96Q38520438-AE5E9890-B177-4F49-A2AE-CEDDD11AD26CQ38620229-B069578A-2779-4668-AB72-2C0F2BBD2809Q38823785-3154F560-38AC-46B1-A8C2-A2DFAC82A7E5Q39730445-65B286E1-AFB0-453D-9D28-A2A12B5458AEQ39776744-0A4B7362-C155-48B3-AC72-2305F656EC96Q40188432-C5422A87-0AB7-4881-8DD4-5C1CC33157EAQ46520584-78939EE8-28F6-4F20-91B2-26C9324AC542Q51082140-AB888650-A78F-4C1F-BF47-D9D7B1C93A61
P2860
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Small molecule kinase inhibito ...... to Parkinson's disease models.
@ast
Small molecule kinase inhibito ...... to Parkinson's disease models.
@en
type
label
Small molecule kinase inhibito ...... to Parkinson's disease models.
@ast
Small molecule kinase inhibito ...... to Parkinson's disease models.
@en
prefLabel
Small molecule kinase inhibito ...... to Parkinson's disease models.
@ast
Small molecule kinase inhibito ...... to Parkinson's disease models.
@en
P2093
P2860
P356
P1476
Small molecule kinase inhibito ...... to Parkinson's disease models
@en
P2093
Fabio Lo Monte
Ghislaine Marlyse Okala Amombo
Stefan Göring
Thomas Kramer
P2860
P304
P356
10.1021/CN200117J
P577
2012-01-18T00:00:00Z